X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs TORRENT PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH TORRENT PHARMA STERLING BIOTECH/
TORRENT PHARMA
 
P/E (TTM) x -0.4 50.9 - View Chart
P/BV x 0.0 6.9 0.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   TORRENT PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
TORRENT PHARMA
Mar-18
STERLING BIOTECH/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs111,550 0.7%   
Low Rs31,144 0.3%   
Sales per share (Unadj.) Rs26.8354.7 7.6%  
Earnings per share (Unadj.) Rs-15.040.1 -37.3%  
Cash flow per share (Unadj.) Rs-5.564.2 -8.5%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs54.9273.1 20.1%  
Shares outstanding (eoy) m267.87169.22 158.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.8 6.8%   
Avg P/E ratio x-0.533.6 -1.4%  
P/CF ratio (eoy) x-1.321.0 -6.1%  
Price / Book Value ratio x0.14.9 2.6%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m1,862227,897 0.8%   
No. of employees `0001.414.7 9.2%   
Total wages/salary Rs m54711,353 4.8%   
Avg. sales/employee Rs Th5,303.34,083.0 129.9%   
Avg. wages/employee Rs Th403.8772.3 52.3%   
Avg. net profit/employee Rs Th-2,959.0461.3 -641.4%   
INCOME DATA
Net Sales Rs m7,18160,021 12.0%  
Other income Rs m432,988 1.4%   
Total revenues Rs m7,22363,009 11.5%   
Gross profit Rs m94713,493 7.0%  
Depreciation Rs m2,5434,086 62.2%   
Interest Rs m4,3773,085 141.9%   
Profit before tax Rs m-5,9319,310 -63.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,529 -76.1%   
Profit after tax Rs m-4,0076,781 -59.1%  
Gross profit margin %13.222.5 58.7%  
Effective tax rate %32.427.2 119.5%   
Net profit margin %-55.811.3 -493.8%  
BALANCE SHEET DATA
Current assets Rs m14,33552,623 27.2%   
Current liabilities Rs m49,80952,022 95.7%   
Net working cap to sales %-494.01.0 -49,296.1%  
Current ratio x0.31.0 28.5%  
Inventory Days Days403120 337.3%  
Debtors Days Days17176 223.9%  
Net fixed assets Rs m55,43285,016 65.2%   
Share capital Rs m268846 31.7%   
"Free" reserves Rs m13,93545,376 30.7%   
Net worth Rs m14,70146,222 31.8%   
Long term debt Rs m9,47841,115 23.1%   
Total assets Rs m73,988142,432 51.9%  
Interest coverage x-0.44.0 -8.8%   
Debt to equity ratio x0.60.9 72.5%  
Sales to assets ratio x0.10.4 23.0%   
Return on assets %0.56.9 7.2%  
Return on equity %-27.314.7 -185.8%  
Return on capital %-6.414.2 -45.3%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86014,580 12.8%   
Fx outflow Rs m253,600 0.7%   
Net fx Rs m1,83510,980 16.7%   
CASH FLOW
From Operations Rs m1,7198,942 19.2%  
From Investments Rs m-3,148-47,070 6.7%  
From Financial Activity Rs m1,42634,174 4.2%  
Net Cashflow Rs m-3-3,655 0.1%  

Share Holding

Indian Promoters % 33.9 71.5 47.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 9.9 12.6 78.6%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 8.8 446.6%  
Shareholders   21,482 26,511 81.0%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare STERLING BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; ITC & Reliance Top Gainers(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading mixed with stocks in the energy sector and realty sector witnessing maximum buying interest.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

This Created Multibagger Stocks in the US and Japan and Now It's Happening in India(The 5 Minute Wrapup)

Jan 17, 2019

It may not just create tremendous stock market wealth, but also push several Indian companies in the reckoning of global leaders.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

Sensex 100,000 Will Happen and I Want You to Profit from It(Profit Hunter)

Jan 18, 2019

These indicators reveal that the interest in stock market investing is only growing and set to grow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS